Dr Agarwal's Health Care Reports Impressive 54.5% PAT Growth in Q3 FY2026
Dr Agarwal's Health Care Ltd, a leading comprehensive eye care provider based in Chennai, has announced outstanding financial results for the third quarter of the fiscal year 2025-2026. The company reported a significant 54.5% year-on-year increase in its consolidated profit after tax (PAT), reaching ₹44 crore for the October-December 2025 quarter.
Quarterly and Nine-Month Performance Highlights
During the corresponding quarter of the previous financial year, the company had earned a profit after tax of ₹28 crore. The latest figures represent substantial growth, reflecting the company's strong operational execution and market expansion strategies.
For the nine-month period ending December 31, 2025, the profit after tax demonstrated even more impressive growth, surging by 74.3% to ₹118 crore. This marks a substantial increase from the ₹68 crore registered during the same period in the previous financial year.
Revenue Growth and Income Performance
The consolidated total income for the quarter under review showed healthy growth, increasing to ₹540 crore from ₹443 crore recorded in the same quarter of the last financial year. This represents a solid performance across the company's operations.
For the April-December 2025 period, the total income demonstrated remarkable growth, soaring to ₹1,548 crore from ₹1,281 crore recorded in the corresponding period of the previous financial year. This consistent upward trajectory indicates sustained business momentum.
CEO's Perspective on Financial Performance
Dr Adil Agarwal, CEO of Dr Agarwal's Health Care Ltd, commented on the company's financial achievements, stating, "The company delivered a strong performance in Q3 marked by robust growth across revenues and profitability, reflecting sustained execution momentum."
He further elaborated on the operational drivers, noting that revenue from operations grew by 23% year-on-year to ₹530 crore for the quarter ended December 2025. This growth was primarily driven by:
- Healthy patient volumes across facilities
- Strong traction in mature centers
- Improving contribution from newer facilities
EBITDA Growth and Operational Resilience
The company's EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortisation) showed impressive growth, increasing by 21.3% to ₹155 crore. Dr Agarwal emphasized that this performance underscores the resilience of the company's operating model and disciplined cost management practices.
Future Growth Strategy
Looking ahead, Dr Agarwal outlined the company's strategic focus, stating, "The company remains focused on accelerating organic growth through aggressive greenfield expansion, deepening its presence in existing markets while selectively entering new geographies."
The company plans to leverage its established brand strength and scalable platform to drive sustainable growth while maintaining its commitment to high standards of patient safety and clinical quality. This balanced approach to expansion and quality maintenance positions Dr Agarwal's Health Care for continued success in the competitive healthcare sector.
The strong Q3 performance demonstrates the company's ability to capitalize on growing demand for specialized eye care services while effectively managing operational costs and expanding its market presence through strategic initiatives.
